Home> Products> improve insulin sensitivity and secretion

{ "products": [ { "_id": "6911af10f122e2a45d230b07", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg & Glimepirde 2 mg", "description": "Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 2 mg is a triple-combination oral anti-diabetic medication formulated to achieve optimal blood sugar control in adults with Type 2 Diabetes Mellitus (T2DM). This unique blend brings together three complementary agents — Sitagliptin (a DPP-4 inhibitor), Metformin (a biguanide), and Glimepiride (a sulfonylurea) — that work through distinct mechanisms to enhance glucose regulation, improve insulin sensitivity, and support overall metabolic balance.\n\nThis advanced combination therapy is prescribed when monotherapy or dual therapy fails to achieve adequate glycemic control. It helps reduce both fasting plasma glucose (FPG) and postprandial glucose (PPG) levels, promoting stable long-term glycemic management.\n\nUses of Sitagliptin + Metformin + Glimepiride\n\nThis fixed-dose combination is primarily indicated for the management of Type 2 Diabetes Mellitus in adults. It is especially beneficial for patients whose blood sugar levels remain uncontrolled despite treatment with Metformin and Glimepiride or Metformin and Sitagliptin alone.\n\nIts main objectives include:\n\nControlling elevated blood glucose levels in adults with Type 2 diabetes\n\nReducing the risk of diabetes-related complications such as neuropathy, nephropathy, and cardiovascular diseases\n\nSupporting better insulin utilization by the body\n\nComplementing diet, exercise, and lifestyle modification to maintain optimal glycemic balance\n\nMechanism of Action\n\nEach component of this combination plays a vital role in maintaining blood sugar control:\n\nSitagliptin (50 mg) – A Dipeptidyl Peptidase-4 (DPP-4) inhibitor that enhances the activity of incretin hormones. These hormones stimulate insulin release and suppress glucagon production when blood glucose levels rise, thereby improving post-meal glucose control.\n\nMetformin Hydrochloride (1000 mg) – A biguanide that lowers glucose production in the liver and increases the body’s sensitivity to insulin. It also decreases intestinal glucose absorption, making it an essential first-line therapy in diabetes management.\n\nGlimepiride (2 mg) – A sulfonylurea that stimulates pancreatic beta cells to release more insulin, especially when blood glucose levels are high. It works synergistically with Metformin and Sitagliptin for more effective glycemic control.\n\nKey Benefits\n\nTriple Mechanism for Superior Control:\nBy combining three potent agents, the medication addresses multiple pathways of glucose regulation—insulin secretion, insulin sensitivity, and hepatic glucose output—resulting in comprehensive and consistent control of blood sugar levels.\n\nEffective Glycemic Stability:\nThe combination helps maintain target HbA1c levels and reduces both fasting and post-meal glucose spikes without significant weight gain when used with proper diet and exercise.\n\nReduced Risk of Diabetic Complications:\nLong-term blood sugar control minimizes the risk of complications such as kidney disease, vision problems, nerve damage, and heart conditions associated with uncontrolled diabetes.\n\nConvenient Fixed-Dose Formulation:\nCombining three medications into a single tablet simplifies dosing schedules, improves patient adherence, and reduces pill burden, which is crucial for long-term treatment success.\n\nImproved Insulin Efficiency:\nEnhances the body's natural insulin response and glucose metabolism, allowing for smoother daily energy levels and reduced fatigue associated with hyperglycemia.\n\nPossible Side Effects\n\nWhile this combination is generally well tolerated, some patients may experience side effects, especially at the beginning of therapy. Common and rare side effects include:\n\nHypoglycemia (low blood sugar): More likely when meals are skipped or during excessive physical exertion. Symptoms include sweating, dizziness, and rapid heartbeat.\n\nGastrointestinal disturbances: Such as nausea, vomiting, diarrhea, abdominal discomfort, or loss of appetite (mostly due to Metformin).\n\nHeadache or Weakness: Usually mild and transient.\n\nAllergic reactions: Rarely, rash or itching may occur.\n\nLactic Acidosis (rare but serious): A potential complication of Metformin, particularly in patients with kidney impairment or excessive alcohol consumption.\n\nWeight gain: Mild weight gain may occur due to Glimepiride’s insulin-enhancing effect.\n\nPrecautions:\n\nRegular monitoring of blood sugar levels and kidney function is essential.\n\nAvoid alcohol and consult a doctor before using this medicine if you have liver or kidney disease.\n\nThe medication should not be used in patients with Type 1 diabetes or diabetic ketoacidosis.\n\nConclusion\n\nThe combination of Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 2 mg represents a powerful and balanced therapy for adults with Type 2 Diabetes Mellitus, especially those requiring triple-drug intervention to achieve desired glycemic control. Its multi-targeted approach ensures effective management of both fasting and postprandial glucose levels, thereby improving long-term metabolic health and reducing the risk of complications.", "price": 295.0, "discountamount": 89.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2197, "imageuri": "https://productimages.withfloats.com/actual/6911af137e4c90e1dc453884.png", "tileimageuri": "https://productimages.withfloats.com/tile/6911af137e4c90e1dc453884.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-11-10T09:23:28.795Z", "updatedon": "2025-11-10T09:27:11.643Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-50-mg-metformin-hydrochloride-1000-mg-glimepirde-2-mg/2197", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ST GLIPTIN GM 50+1000+2 ", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68fcb453ba48b3ee8857fd47", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin Phosphate Monhydrate 64.25 mg, Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg & Glimepirde 1 mg", "description": "ST GLIPTIN GM is a high-quality, fixed-dose combination oral antidiabetic medication containing Sitagliptin 50 mg, Metformin Hydrochloride 1000 mg, and Glimepiride 1 mg. This triple-combination therapy is specifically formulated to provide effective glycemic control in adults with type 2 diabetes mellitus (T2DM) who require multiple agents to achieve adequate blood sugar control.\nST GLIPTIN GM works through complementary mechanisms to target the core pathophysiological defects of T2DM—insulin resistance, impaired insulin secretion, and increased hepatic glucose output—making it an ideal choice for patients requiring intensified therapy.\nKey Indications:\nST GLIPTIN GM is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when dual therapy with any two of the individual components (Sitagliptin, Metformin, or Glimepiride) does not provide adequate control.\nMechanism of Action:\nSitagliptin (50 mg):\nA Dipeptidyl Peptidase-4 (DPP-4) inhibitor that enhances the levels of active incretin hormones (GLP-1 and GIP), increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner.\nMetformin Hydrochloride (1000 mg):\nA biguanide that improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake.\nGlimepiride (1 mg):\nA sulfonylurea that stimulates pancreatic β-cells to secrete insulin, thereby reducing blood glucose levels.\nThe combination targets multiple metabolic pathways to provide synergistic and sustained blood glucose control.\nDosage and Administration:\nRecommended Dose:\nOne tablet daily, preferably with meals to reduce gastrointestinal side effects.\nIndividualization Required:\nDosage should be tailored based on patient response, renal function, and physician assessment.\nRenal Monitoring:\nBaseline and periodic assessment of renal function is advised, particularly due to the metformin component.\nKey Benefits of ST GLIPTIN GM 50/1000/1:\nTriple Mechanism of Action:\nTargets insulin resistance, insufficient insulin secretion, and excessive hepatic glucose production.\nEnhanced Glycemic Control:\nEffective in achieving and maintaining HbA1c targets.\nOnce-Daily Convenience:\nImproves adherence by reducing pill burden in patients requiring combination therapy.\nWeight Neutral to Modest Reduction:\nMetformin and sitagliptin components support weight neutrality.\nLow Hypoglycemia Risk:\nSitagliptin and metformin carry minimal hypoglycemia risk; however, glimepiride may increase the risk—monitor accordingly.\nSafety and Precautions:\nHypoglycemia:\nMay occur, particularly due to the glimepiride component. Educate patients on recognizing and managing low blood sugar.\nLactic Acidosis:\nA rare but serious complication of metformin. Avoid in patients with significant renal impairment or conditions predisposing to hypoxia.\nRenal Function:\nDose adjustment or discontinuation may be needed based on renal function.\nPancreatitis:\nRare reports with DPP-4 inhibitors like sitagliptin. Discontinue if suspected.\nAllergic Reactions:\nDiscontinue use if hypersensitivity reactions occur.\nPossible Side Effects:\nWhile ST GLIPTIN GM is generally well-tolerated, some patients may experience:\nNausea\nDiarrhea\nHeadache\nHypoglycemia (especially in elderly or with missed meals)\nAbdominal discomfort\nUpper respiratory tract infections\nDizziness\nFlatulence\nIf any side effects persist or worsen, seek immediate medical advice.\nStorage Instructions:\nStore at a temperature below 30°C.\nProtect from moisture and direct sunlight.\nKeep out of reach of children.\nWhy Choose ST GLIPTIN GM 50/1000/1?\nST GLIPTIN GM provides a powerful and synergistic combination of three well-established antidiabetic agents in a single, convenient daily dose. It offers a comprehensive approach to managing type 2 diabetes by addressing multiple metabolic abnormalities with a focus on safety, efficacy, and patient compliance. Manufactured under stringent GMP-certified conditions, ST GLIPTIN GM ensures quality, reliability, and therapeutic confidence for both patients and prescribers.", "price": 285.0, "discountamount": 86.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2188, "imageuri": "https://productimages.withfloats.com/actual/68fcb456f31288eaa96accfa.png", "tileimageuri": "https://productimages.withfloats.com/tile/68fcb456f31288eaa96accfa.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-10-25T11:28:19.425Z", "updatedon": "2025-10-25T13:16:42.121Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-phosphate-monhydrate-64-25-mg-sitagliptin-50-mg-metformin-hydrochloride-1000-mg-glimepirde-1-mg/2188", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ST GLIPTIN GM 50+1000+1", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "68e7a474f3481c1f16d3b038", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin (50mg), Metformin Hydrochloride (500mg) & Glimepiride (2mg)", "description": "Sitagliptin 50mg, Metformin Hydrochloride 500mg & Glimepiride 2mg is a combination oral medication designed for the effective management of type 2 diabetes mellitus. This triple-action formula works synergistically to control blood glucose levels by addressing insulin resistance, enhancing insulin secretion, and regulating post-meal sugar spikes. Ideal for patients who require more than one mechanism to maintain stable blood sugar, this combination is often prescribed when monotherapy or dual therapy is insufficient.\n\nUses\n\nManagement of Type 2 Diabetes Mellitus in adults.\n\nHelps in controlling fasting and postprandial blood glucose levels.\n\nRecommended for patients whose blood sugar is not adequately controlled with a single antidiabetic medicine.\n\nCan be used as part of a comprehensive diabetes management plan, including diet and exercise.\n\nKey Benefits\n\nDual Mechanism Control:\n\nMetformin Hydrochloride reduces hepatic glucose production and improves insulin sensitivity.\n\nGlimepiride stimulates pancreatic beta cells to secrete more insulin.\n\nSitagliptin enhances incretin hormones, leading to better regulation of post-meal glucose levels.\n\nEffective Blood Sugar Management:\nHelps maintain optimal fasting and postprandial glucose levels, reducing the risk of diabetes-related complications.\n\nConvenient Combination Therapy:\nCombines three mechanisms in a single tablet, reducing the pill burden and improving patient compliance.\n\nSupports Overall Health:\nHelps prevent long-term complications such as neuropathy, nephropathy, retinopathy, and cardiovascular risks associated with diabetes.\n\nPossible Side Effects\n\nWhile generally well-tolerated, some patients may experience:\n\nGastrointestinal issues: nausea, vomiting, diarrhea, or abdominal discomfort (mainly from Metformin).\n\nHypoglycemia (low blood sugar): more likely due to Glimepiride; symptoms include dizziness, sweating, or shakiness.\n\nAllergic reactions: rash, itching, or swelling in rare cases.\n\nOther mild effects: headache, fatigue, or minor changes in taste.\n\nNote: Patients should always consult their doctor before starting this combination and report any unusual symptoms immediately.\n\nConclusion\n\nThe Sitagliptin, Metformin Hydrochloride & Glimepiride combination provides a powerful, multi-targeted approach to managing type 2 diabetes. By tackling high blood sugar from different angles, it supports better glucose control, enhances overall quality of life, and reduces the risk of diabetes-related complications. When used alongside proper diet, exercise, and medical guidance, this combination can be a cornerstone in effective diabetes management.", "price": 180.0, "discountamount": 54.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2185, "imageuri": "https://productimages.withfloats.com/actual/68e7a47b040520d37b5e6b34.png", "tileimageuri": "https://productimages.withfloats.com/tile/68e7a47b040520d37b5e6b34.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-10-09T12:03:00.012Z", "updatedon": "2025-10-09T12:03:00.012Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-50mg-metformin-hydrochloride-500mg-glimepiride-2mg-/2185", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ST GLIPTIN GM", "category": "", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "68822dd35b399ba6097ed11b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "SEIZMET G 0.5 FORTE", "description": "SEIZMET G0.5 FORTE is a powerful oral antidiabetic medication formulated with a combination of glimepiride and metformin hydrochloride. This dual-action therapy is specifically designed for patients with type 2 diabetes mellitus who are unable to control their blood sugar levels with diet and exercise alone. The combination works in synergy to manage blood glucose effectively, reduce insulin resistance, and improve overall glycemic control.\n\nGlimepiride and metformin hydrochloride tablets are a combination medication used to treat type 2 diabetes. They work by helping the pancreas release more insulin and by reducing the amount of sugar produced by the liver, while also making the body more sensitive to insulin.\n\nWhat is SEIZMET G0.5 FORTE?\nSEIZMET G0.5 FORTE contains two active ingredients:\n\nGlimepiride (0.5 mg): A sulfonylurea class drug that stimulates the beta cells of the pancreas to release insulin.\n\nMetformin Hydrochloride: A biguanide that works primarily by suppressing hepatic glucose production and increasing insulin sensitivity in muscles.\n\nTogether, this combination addresses both insulin deficiency and resistance—two key factors in type 2 diabetes.\n\nUses of SEIZMET G0.5 FORTE:\n\nEffective in managing type 2 diabetes mellitus\n\nHelps in reducing fasting and postprandial blood glucose levels\n\nUsed as monotherapy or in combination with other antidiabetic agents\n\nReduces the risk of diabetic complications such as nephropathy, retinopathy, and cardiovascular disease\n\nSide Effects of SEIZMET G0.5 FORTE:\nLike all medications, glimepiride and metformin hydrochloride tablets may cause side effects in some patients. Common side effects include:\n\nNausea or vomiting\n\nDiarrhea\n\nHypoglycemia (low blood sugar)\n\nHeadache\n\nDizziness\n\nMetallic taste in the mouth\n\nAbdominal discomfort\n\nIn rare cases, it may cause lactic acidosis, a serious condition related to metformin accumulation.\n\nPrecautions Before Using SEIZMET G0.5 FORTE:\n\nAlways take the medication exactly as prescribed by your doctor.\n\nInform your physician if you have a history of liver or kidney disorders, heart disease, or alcohol abuse.\n\nAvoid excessive alcohol consumption while on this medication as it increases the risk of lactic acidosis.\n\nNot recommended for patients with type 1 diabetes or diabetic ketoacidosis.\n\nRegularly monitor your blood sugar and kidney function.\n\nThis medicine should be used during pregnancy only if absolutely necessary and under medical supervision.\n\nDrug Interactions: What Drugs Interact with SEIZMET G0.5 FORTE?\nCertain medications can interact with glimepiride and metformin, affecting their efficacy or increasing the risk of side effects. These include:\n\nBeta-blockers (e.g., propranolol) – may mask hypoglycemia symptoms\n\nDiuretics – may impair blood sugar control\n\nACE inhibitors – may increase the blood glucose-lowering effect\n\nCorticosteroids – may reduce the effectiveness of the medication\n\nAntipsychotics (e.g., olanzapine)\n\nAlcohol – increases the risk of lactic acidosis\n\nCimetidine – may raise metformin levels in the body\n\nAlways inform your healthcare provider about all medications, supplements, or herbal products you are taking.\n\nConclusion:\nSEIZMET G0.5 FORTE is a trusted, effective choice for managing type 2 diabetes, offering the combined benefits of glimepiride and metformin hydrochloride tablets. With dual mechanisms—enhancing insulin secretion and improving insulin sensitivity—it delivers comprehensive glycemic control. When taken as directed and with regular monitoring, SEIZMET G0.5 FORTE can be a valuable part of a diabetic patient’s treatment regimen, contributing to a healthier, more balanced life.\n\nFor best results, pair this medication with a proper diet, regular physical activity, and periodic blood glucose testing. Always consult your healthcare provider for personalized advice.", "price": 125.0, "discountamount": 38.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2151, "imageuri": "https://productimages.withfloats.com/actual/68822dd8296c4d19d55e8535.png", "tileimageuri": "https://productimages.withfloats.com/tile/68822dd8296c4d19d55e8535.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-07-24T12:57:55.385Z", "updatedon": "2025-07-24T12:57:55.385Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/seizmet-g-0-5-forte/2151", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "glimepiride and metformin hydrochloride tablets", "category": "DIABETIC RANGE", "tags": [ "glimepiride and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "681c5e9e5a26e4010ea42029", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "ST-GLIPTIN M 100/ 1000", "description": "ST-GLIPTIN M 100/1000 is an advanced oral antidiabetic medication designed for the effective management of Type 2 Diabetes Mellitus. This powerful combination of Sitagliptin (100 mg) and Metformin Hydrochloride (1000 mg) offers dual action in controlling elevated blood glucose levels, especially in patients who do not respond adequately to metformin or sitagliptin alone. It is intended for adults and is generally used in conjunction with diet and exercise to enhance glycemic control.\n\nKey Ingredients\nSitagliptin (100 mg)\nSitagliptin is a DPP-4 (Dipeptidyl Peptidase-4) inhibitor that increases the levels of incretin hormones, which help regulate blood sugar by increasing insulin release and decreasing glucagon levels.\n\nMetformin Hydrochloride (1000 mg)\nMetformin belongs to the biguanide class of antidiabetics. It works by reducing the amount of sugar produced by the liver and improves the body’s sensitivity to insulin, facilitating better glucose utilization.\n\nKey Benefits\nHelps reduce both fasting and postprandial (after-meal) blood glucose levels effectively\nImproves overall glycemic control in patients with Type 2 diabetes\nCombines two different mechanisms of action for better diabetes management\nMinimizes the risk of hypoglycemia compared to other antidiabetic therapies\nMay support weight neutrality or slight weight loss in diabetic individuals\n\nHow Does It Work?\nST-GLIPTIN M 100/1000 works through a synergistic mechanism by combining two effective antidiabetic agents:\n\nSitagliptin enhances the levels of incretin hormones, which help the pancreas produce more insulin and reduce the secretion of glucagon, especially when blood sugar is high.\nMetformin reduces hepatic glucose production and increases insulin sensitivity, which helps the body use glucose more efficiently.\nTogether, these agents provide comprehensive blood sugar control by addressing multiple physiological pathways involved in glucose metabolism.\n\nDirections for Use\nTake ST-GLIPTIN M 100/1000 exactly as prescribed by your physician.\nIt is typically taken once or twice daily with meals to reduce gastrointestinal side effects and optimize absorption.\nSwallow the tablet whole with water. Do not crush or chew the tablet.\nMaintain a balanced diet and follow an active lifestyle for best results.\nRegular blood sugar monitoring is essential to assess effectiveness and make any necessary dosage adjustments.\n\nSide Effects\nCommon side effects may include nausea, diarrhea, stomach upset, or headache.\nSome individuals may experience respiratory tract infections, sore throat, or a runny nose.\nLactic acidosis is a rare but serious side effect associated with high-dose metformin—seek immediate medical attention if symptoms like unusual fatigue, muscle pain, difficulty breathing, or abdominal discomfort occur.\nAllergic reactions such as rash, itching, or swelling are uncommon but possible.\nAlways inform your doctor of any persistent or bothersome side effects for timely intervention.", "price": 225.0, "discountamount": 68.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "1001000 works", "100 1000stgliptin", "work stgliptin", "balanced diet", "tablet maintain", "diabetic individuals", "sitagliptin 100 mg", "timely intervention", "rash itching", "medical attention", "highdose metforminseek", "assess effectiveness", "active lifestyle", "pancreas produce", "synergistic mechanism", "antidiabetic therapies", "hypoglycemia compared", "glycemic control", "biguanide class", "incretin hormones", "respond adequately", "powerful combination", "insulin facilitating", "sugar produced", "side effect", "bodys sensitivity", "effective management", "blood sugar", "increases insulin sensitivity", "regulate blood sugar", "glucose metabolism directions", "increasing insulin release", "bothersome side effects", "diabetes management minimizes", "optimize absorption swallow", "slight weight loss", "support weight neutrality" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2107, "imageuri": "https://productimages.withfloats.com/actual/681c5e9f5e6dd8f19a0309c3.png", "tileimageuri": "https://productimages.withfloats.com/tile/681c5e9f5e6dd8f19a0309c3.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-05-08T07:34:54.516Z", "updatedon": "2025-05-08T07:35:36.782Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/st-gliptin-m-100-1000/2107", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "sitagliptin and metformin hydrochloride tablets", "category": "DIABETIC RANGE", "tags": [ "Sitagliptin and Metformin hydrochloride tablets Uses in Hindi", "sitagliptin and metformin hydrochloride tablets 50/1000 uses in hindi", "sitagliptin and metformin hydrochloride tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "67e1547f527b20030c4156f0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin 5 mg and Metformin Hydrochloride 500 mg", "description": "EMPATECH MET 5/500 is a powerful combination of Empagliflozin 5 mg and Metformin Hydrochloride 500 mg designed to effectively manage Type 2 Diabetes Mellitus. It helps control blood sugar levels, improves insulin sensitivity, and reduces the risk of diabetes-related complications. This dual-action formula works by limiting glucose absorption while enhancing the body's natural ability to utilize insulin, making it a preferred choice for diabetic patients seeking optimal glycemic control.\n \nKey Benefits:\nEffective Blood Sugar Control – Lowers HbA1c levels and maintains stable glucose levels.\nSupports Weight Management – Promotes calorie loss by eliminating excess glucose.\nReduces Cardiovascular Risk – Empagliflozin has heart-protective benefits, reducing the risk of heart-related complications.\nImproves Insulin Sensitivity – Helps the body use insulin more effectively.\nReduces the Risk of Hypoglycemia – Lowers blood sugar without excessive insulin spikes.\n\nHow Does It Work?\n\nEmpagliflozin blocks the SGLT2 (Sodium-Glucose Co-Transporter 2) in the kidneys, preventing glucose reabsorption and allowing excess sugar to be excreted through urine.\nMetformin decreases glucose production in the liver and enhances insulin sensitivity, helping the body use glucose more efficiently.\nTogether, they provide comprehensive diabetes management by regulating blood sugar without causing significant hypoglycemia.\n \nDirections for Use:\n \n\nTake EMPATECH MET 5/500 as prescribed by your doctor.\n\nSwallow the tablet whole with water, preferably with meals to minimize stomach discomfort.\n\nMaintain a balanced diet and regular exercise for optimal results.\n\nDo not stop or change the dosage without consulting your doctor.\n\n \nSide Effects:\n \n\nWhile EMPATECH MET 5/500 is generally well-tolerated, some individuals may experience:\n\nFrequent Urination – Due to glucose excretion in urine.\nMild Stomach Discomfort – Including nausea, bloating, or diarrhea.\nDizziness or Weakness – Especially in the initial stages of treatment.\nUrinary Tract Infections (UTIs) – A possible side effect of increased glucose in urine.\nLactic Acidosis (Rare but Serious) – Symptoms include muscle pain, breathing difficulty, or extreme tiredness; seek medical attention if these occur.", "price": 115.0, "discountamount": 35.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "effectively reduces", "increased glucose", "initial stages", "diarrhea dizziness", "nausea bloating", "glucose excretion", "generally welltolerated", "optimal results", "regular exercise", "balanced diet", "water preferably", "empatech met 5500", "preferred choice", "diabetesrelated complications", "powerful combination", "side effect", "doctor swallow", "empagliflozin 5mg", "doctor side effects", "limiting glucose absorption", "excessive insulin spikes", "utilize insulin making", "work empagliflozin blocks", "regulating blood sugar", "allowing excess sugar", "heartprotective benefits reducing", "bodys natural ability", "dualaction formula works" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2074, "imageuri": "https://productimages.withfloats.com/actual/67e15496bb48c9c5202ecea6.png", "tileimageuri": "https://productimages.withfloats.com/tile/67e15496bb48c9c5202ecea6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-03-24T12:47:59.972Z", "updatedon": "2025-03-27T12:53:02.808Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-5-mg-and-metformin-hydrochloride-500-mg/2074", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "EMPATECH MET 5/500", "category": "DIABETIC RANGE", "tags": [ "empagliflozin/metformin 5 mg/1000 mg", "empagliflozin 12.5 mg+metformin 500 mg price", "empagliflozin + metformin combination brand name" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "670cec40396e427ba56d673c", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Gliclazide IP (40 mg), Metformin Hydrochloride IP (500 mg), Voglibose IP (0.3 mg)", "description": "GLICLAGLAZE TRIO 40/0.3 is a prescription medication used for managing type 2 diabetes. It contains a combination of three active ingredients—Gliclazide IP (40 mg), Metformin Hydrochloride IP (500 mg), and Voglibose IP (0.3 mg)—each targeting different pathways to help control blood sugar levels.\n\n \nKey Benefits:\n \n\nProvides comprehensive blood sugar control for patients with type 2 diabetes.\nReduces fasting and post-meal glucose levels.\nLowers the risk of complications associated with high blood sugar, such as cardiovascular issues and neuropathy.\n \nHow Does It Work?\n \n\nGliclazide enhances insulin secretion from the pancreas.\nMetformin decreases glucose production in the liver and improves insulin sensitivity.\nVoglibose slows the breakdown of carbohydrates in the intestines, minimizing sudden spikes in blood sugar levels after meals.\n \nDirections for Use:\n \n\nTake this medication as directed by your healthcare provider, typically once or twice daily with meals.\nSwallow the tablet whole with water.\nDo not crush or chew the tablet.\nRegularly monitor your blood sugar levels as advised by your doctor.\n \nSide Effects:\n \n\nCommon: Nausea, diarrhea, stomach pain, and low blood sugar (hypoglycemia).\nLess Common: Headaches, dizziness, and mild gastrointestinal discomfort.\nRare but Severe: Severe hypoglycemia, lactic acidosis (with metformin), or allergic reactions.", "price": 205.0, "discountamount": 61.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "stomach pain", "Side Effects", "Key Benefits", "Voglibose IP", "sudden spikes", "Gliclazide IP", "lactic acidosis", "type 2 diabetes", "low blood sugar", "GLICLAGLAZE TRIO", "high blood sugar", "insulin secretion", "allergic reactions", "different pathways", "glucose production", "blood sugar levels", "Severe hypoglycemia", "healthcare provider", "insulin sensitivity", "cardiovascular issues", "prescription medication", "post-meal glucose levels", "three active ingredients", "Metformin Hydrochloride IP", "mild gastrointestinal discomfort", "comprehensive blood sugar control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1990, "imageuri": "https://productimages.withfloats.com/actual/670cec44d902143eb0bc8e8e.png", "tileimageuri": "https://productimages.withfloats.com/tile/670cec44d902143eb0bc8e8e.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-10-14T10:02:40.431Z", "updatedon": "2024-10-14T10:02:40.431Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclazide-ip-40-mg-metformin-hydrochloride-ip-500-mg-voglibose-ip-0-3-mg-/1990", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": " GLICLAGLAZE TRIO 40/0.3 ", "category": "DIABETIC RANGE", "tags": [ "Vildagliptin and voglibose combination", "Glimepiride, Metformin hydrochloride er Voglibose ", "Glimepiride 3mg Metformin (500mg Voglibose 0.3mg b" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "668e77e853fc1c2298508399", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nTENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy.\n\nComposition\n\nTeneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels.\nPioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production.\nMechanism of Action\n\nTeneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion.\nPioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production.\nIndications\nTENELIGOLD PIO 20/15 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications.\nDosage and Administration\n\nThe typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals.\nDosage adjustments may be necessary based on individual patient response and tolerability.\nIt is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control.\nSide Effects\nCommon side effects may include:\n\nHypoglycemia (especially when used in combination with insulin or sulfonylureas)\nEdema (fluid retention)\nWeight gain\nHeadache\nNasopharyngitis (common cold)\nMore severe side effects can include:\n\nHeart failure (especially in patients with pre-existing cardiovascular disease)\nHepatic dysfunction (monitor liver function tests periodically)\nBone fractures (especially in women)\nPrecautions\n\nHeart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases.\nBladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors.\nLiver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction.\nPregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks.\nDrug Interactions\n\nInsulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas.\nGemfibrozil: May increase Pioglitazone levels, requiring dose adjustment.\nCYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects.\nConclusion\nTENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "one tablet", "Weight gain", "common cold", "risk factors", "dual therapy", "Heart failure", "increased risk", "dosage regimen", "typical dosage", "Bladder Cancer", "Bone fractures", "adipose tissue", "TENELIGOLD PIO", "glucose uptake", "dose adjustment", "fluid retention", "glucagon release", "DPP-4) inhibitor", "safety parameters", "CYP2C8 Inhibitors", "Drug Interactions", "incretin hormones", "different aspects", "Regular monitoring", "treatment outcomes", "Dosage adjustments", "peripheral tissues", "single formulation", "glucagon secretion", "potential benefits", "glucose metabolism", "insulin sensitivity", "Pioglitazone levels", "Hepatic dysfunction", "Common side effects", "different mechanisms", "dual-action approach", "liver function tests", "blood glucose levels", "dipeptidyl peptidase-4", "healthcare professional", "optimal glycemic control", "type 2 diabetes mellitus", "More severe side effects", "potential adverse effects", "hepatic glucose production", "Pioglitazone concentrations", "individual patient response", "two antidiabetic medications", "other cardiovascular diseases", "other antidiabetic medications", "existing cardiovascular disease", "glucose-dependent insulin secretion", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1935, "imageuri": "https://productimages.withfloats.com/actual/668e77ebf07c99c3af8e6d67.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e77ebf07c99c3af8e6d67.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:00:40.528Z", "updatedon": "2024-07-10T12:00:40.528Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pio-20-15-/1935", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "teneligliptin + pioglitazone brand name", "Zita Plus Pio", "Teneligliptin + Pioglitazone Metformin", "Zita Piomet 1000", "Teneligliptin 20 MG and Pioglitazone 15 MG tablets", "Dapagliflozin", "Zita Piomet 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }